Novo Nordisk is paying $240 million up front for global rights to zaltenibart, an Omeros drug that blocks the MASP-3 protein to treat diseases caused by excessive activity of the complement system.
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, ...
Omeros Corporation (NASDAQ:OMER) is one of the Reddit stocks that will go to the moon. On October 15, Omeros Corporation and ...
Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 ...
Denmark: Novo Nordisk and Omeros Corporation have announced that they have entered into a definitive asset purchase and ...
Omeros' stock surged over 150% after licensing zaltenibart to Novo Nordisk for $240M upfront, plus milestones and royalties.
News-Medical.Net on MSN
Hormone replacement therapy may reverse menopause-related immune changes
A study led by researchers at Queen Mary University of London has found that hormone replacement therapy (HRT) may help ...
The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...
The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory ...
New research suggests Covid-19 mRNA vaccines offer benefits beyond viral protection. These vaccines may boost the immune ...
Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback